Opioid and cocaine use epidemic is entrenched within Baltimore city, and there are no FDA-approved treatment for any stimulant disorders.At the University of Maryland, Baltimore, researchers are exploring how GLP-1 receptor agonists — a class of drugs commonly used for weight loss — may offer new hope for people with cocaine use disorder. This is just one example of how federally funded research at UMB is Changing The Future Today.Hear from Sarah Kattakuzhy, MD, co-director for the Research Initiative on Infectious Disease and Substance Use Disorder, at the University of Maryland School of Medicine explains. Kattakuzhy is also the associate director of the Kahlert Institute for Addiction Medicine.🧪 Breakthroughs Can’t Wait: UMB research drives innovation, improves lives, and tackles global challenges. But we can’t do it without continued support.🔗 Learn more and support research that saves lives: https://www.umaryland.edu/breakthroughs #BreakthroughsCantWait #NIHfunding #CocaineUseDisorder #GLP1 #AddictionResearch #UMB #ResearchMatters